1-[1-(2-Amino-ethyl)-piperidin-4-yl]-5-chloro-1,3-dihydro-benzoimidazol-2-one | 68146-20-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并咪唑类
• 英文名称: 1-[1-(2-Amino-ethyl)-piperidin-4-yl]-5-chloro-1,3-dihydro-benzoimidazol-2-one
• 英文别名: 3-[1-(2-aminoethyl)piperidin-4-yl]-6-chloro-1H-benzimidazol-2-one
• CAS: 68146-20-3
• 化学式: C₁₄H₁₉ClN₄O
• 分子量: 294.784
• InChiKey: OHOLPGQWIWNKER-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  61.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  tert-butyl (2-(4-(5-chloro-2-oxo-2,3-dihydro-1H-benzo[d]imidazol-1-yl)piperidin-1-yl)ethyl)carbamate 在 盐酸 作用下， 以 1,4-二氧六环 、 甲醇 为溶剂， 生成 1-[1-(2-Amino-ethyl)-piperidin-4-yl]-5-chloro-1,3-dihydro-benzoimidazol-2-one
  参考文献：
  名称：

  Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures for PLD1 specificity

  摘要：

  This Letter describes the synthesis and structure-activity-relationships (SAR) of isoform-selective PLD inhibitors. By virtue of the installation of alternative halogenated piperidinyl benzimidazolone privileged structures, in combination with a key ( S)-methyl group, novel PLD inhibitors with low nM potency and unprecedented levels of PLD1 isoform selectivity (similar to 1700-fold) over PLD2 were developed. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.02.057

文献信息

• [EN] ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS<br/>[FR] THÉRAPIES ANTIVIRALES AVEC DES INHIBITEURS DE PHOSPHOLIPASE D
  申请人：UNIV VANDERBILT

  公开号：WO2013049773A1

  公开（公告）日：2013-04-04

  Disclosed are methods of treating viral infections comprising, in one aspect, administering compounds that are phospholipase D inhibitors. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention. In accordance with the purpose(s) of the invention, as embodied and broadly described herein, the invention, in one aspect, relates to antiviral therapies. For example, compounds having Phospholipase D activity (e.g., isoform selective Phospholipase D inhibitors) can be useful in antiviral therapies (e.g., influenza treatments).